"We understand from Mylan NV's press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to detected trace amounts of impurity...," Solara Active Pharma Sciences in a filing to BSE.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2NaqkXB
via IFTTT
0 comments:
Post a Comment